How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

SU

NASDAQ:SUPN
Get a brief AI stock analysisSaves ~ 15 minutes of your time

SU

Supernus Pharmaceuticals IncNASDAQ SUPN Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is SUPN undervalued compared to its fair value?

The fair value of SUPN stock is hidden USD. Relative to the market price of 29.9 USD Supernus Pharmaceuticals Inc is hidden.

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs ...[More about valuation]

Supernus Pharmaceuticals Fair Value

Available for registered user
UNLOCK
What is fair value?

Market cap:

1.644 $B

Price:

29.9 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

0.002

FINANCIALS

Supernus Pharmaceuticals financial for reporting period

Income Statement

0.14 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0032 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
0.0001 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.14 B 100%
0.13 B 89%
-0.0032 B -2%
0.0001 B 0%

Balance Sheet

1.3 B
0.93 B

Financial Position Analysis

Assets

1.3 B
Current Assets
0.54 B
Total non-current assets
0.76 B

Total current liabilities
0.31 B
Total non-current liabilities
0.06 B

Cash Flow Statement

0.038 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
0.038 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Supernus Pharmaceuticals fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-2 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
1 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-1 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Supernus Rating

Is SUPN attractive for investment based on fundamental analysis?

SUPN stock rating is hidden. Supernus Pharmaceuticals is a hidden by Eyestock methodology.

Get SUPN Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-3

Gross Margin:

87

CFO / Debt ratio:

hidden

Current ratio:

1.669

Debt / Equity ratio:

ROE:

-2

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

SUPN analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for SUPN to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Supernus Pharmaceuticals Inc dividends

SUPN dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About SUPN stock

About the company Supernus Pharmaceuticals Inc

Market cap $B

1.644

Dividend yield

Shares outstanding

54.3769 B

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 612 full-time employees. The company went IPO on 2010-12-28. The firm is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The firm's diverse neuroscience portfolio includes treatments for epilepsy, migraine, attention deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company is also developing a range of CNS product candidates, including potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced Parkinson's disease (PD).

SUPN profile

  • Ticker

    SUPN

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    28 December 2010

  • Sector

    Healthсare

  • Industry

    Pharmaceuticals

  • Employees

    612

  • City

    Rockville

  • Address

    9715 Key West Avenue

  • Cusip

    868459108

Frequently Asked Questions

What sector does Supernus operate in?

Supernus operates in Healthсare sector

What is market cap of Supernus?

Market cap of Supernus is 1.644 USD as of 24 Jul 2024

What is market price of one SUPN stock?

Market price of one SUPN stock is 29.9 USD as of 24 Jul 2024

What is Supernus revenue?

According to the recent report Supernus revenue is 143.644

What is Supernus net income?

According to the recent report Supernus net icnome is 0.124

What is Supernus net income growh rate?

Net income growth rate of Supernus is -99